NASDAQ · KTRA
Healthcare · Biotechnology
$0.22
Down-$0.01 (-6.31%)
Updated Sep 11, 2026, 2:38 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
KTRA does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning KTRA.
KTRA research
Company profile and research snapshot.
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 14, 2023 | Maxim Group | Buy | — |
| Sep 29, 2022 | Maxim Group | Hold | — |
| May 16, 2022 | Dawson James | Neutral | — |
| Jan 20, 2022 | HC Wainwright & Co. | Buy | — |
| Sep 30, 2021 | Aegis Capital | Buy | — |
No generated briefing is available yet.
Investing.com · Jul 13, 2024
Kintara Therapeutics, a pharmaceutical company, has withdrawn the designation of its Special Voting Preferred Stock and Series B Preferred Stock, reflecting an amendment to its corporate structure.
Zacks Investment Research · Apr 4, 2024
Kintara (KTRA) inks a definitive merger agreement with TuHURA for an all-stock transaction. It is expected to close in the third quarter of 2024. The stock surges 63.4%.
PennyStocks · Apr 4, 2024
Here's how to build a winning trading plan The post 3 Steps to Building a Winning Penny Stocks Trading Plan appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
PennyStocks · Mar 31, 2024
Here's how to size your penny stocks position The post Sizing Your Penny Stocks Position, 3 Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning KTRA.
No results
No recent SID articles mention KTRA.
